Status:
TERMINATED
Inhalation of Low Concentration of CO2 in Preterm Infants Not Responding to Caffeine for the Treatment of Apnea
Lead Sponsor:
University of Manitoba
Collaborating Sponsors:
Manitoba Institute of Child Health
Conditions:
Apnea of Prematurity
Eligibility:
All Genders
3-60 years
Phase:
PHASE2
PHASE3
Brief Summary
In premature infants, apnea of prematurity is one of their major clinical problems. Caffeine is currently a worldwide therapy to reduce the number and severity of these apneas. This practice has shown...
Eligibility Criteria
Inclusion
- gestational age at birth \< 33 weeks
- on caffeine treatment for apnea of prematurity at a maintenance dose of 5 mg/kg/day
- having apnea of prematurity (at least 5 self-resolved apneas or 2 apneas requiring intervention/12 hours)
Exclusion
- on mechanical ventilation
- presence of congenital anomalies, sepsis or other known causes of apnea
- failure to obtain parental consent
Key Trial Info
Start Date :
October 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2014
Estimated Enrollment :
7 Patients enrolled
Trial Details
Trial ID
NCT01911182
Start Date
October 1 2011
End Date
July 1 2014
Last Update
February 19 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Manitoba
Winnipeg, Manitoba, Canada, R3E 0L8